Без рубрики – Page 2

On September 4, 2025, the first international conference and exhibition Ukraine ReHealth 2025 took place in Kyiv at the Parkovy Congress and Exhibition Center—a key event dedicated to the restoration and modernization of Ukraine’s healthcare system following the full-scale invasion.

The event was organized by Impact Bridge LLC in collaboration with the law firm Sayenko Kharenko, the medical company Empirica, and the IT company Sigma Software, with the support of the Ministry of Health of Ukraine. Participants from across the country and international delegations gathered to discuss the extent of the damage, innovative technologies, attracting investment, and ways to build partnerships in the healthcare sector.

Biodrook attended the forum to participate in professional discussions, explore new trends in medicine, and assess the direction of Ukraine’s healthcare system. For us, it was a valuable opportunity to network with colleagues, hear the views of leading experts, and draw inspiration from international best practices.

Ukraine ReHealth 2025 reaffirmed its status as a strategic platform where ideas are formed, partnerships are built, and priorities for the future of medicine are defined.

A New Era of Responsibility and Trust in Medical Device Manufacturing

We are pleased to announce that biodrook has successfully obtained certification for compliance with the international standard DSTU EN ISO 13485:2018—one of the highest industry standards in the field of medical device design and manufacturing.

What is ISO 13485 and why is it important?

ISO 13485 is an international quality management standard specifically designed for medical devices. It regulates all stages of the product lifecycle: from design, development, and manufacturing to post-market monitoring, traceability, and user feedback.

Obtaining this certification means that biodrook’s manufacturing processes meet international safety and quality requirements, and all products undergo rigorous quality control and risk management procedures. biodrook has established a transparent system for documentation, change tracking, and accountability.

Why is this important for doctors, partners, clinics, and patients?

This certification is not just a formality. It is a guarantee of trust:

For clinics and doctors — confidence in the quality of implants and related solutions
For international partners — compliance with global requirements, simplification of import procedures and joint projects
For investors — confirmation of the maturity of internal processes and readiness

Digital Planning

Planning begins with CT or MRI scans and technical specifications from surgeons. A 3D model is created, tailored to clinical needs and the patient’s anatomy.

Regeneration-Supporting Material

biodrook uses a biodegradable composite based on polylactic acid (PLA) with added hydroxyapatite. The material has high biocompatibility and gradually degrades within the body.

3D printing technology

A key stage is the printing of custom products. Biodrook’s technology ensures geometric accuracy, porosity control, and structural stability.

Sterilization and quality control

After printing, the product undergoes low-temperature gas sterilization. Quality control checks: compliance with the geometric parameters of the 3D model, structural integrity, and compliance with medical standards.

Clinical Benefits

Custom biodegradable implants open up new possibilities in reconstructive orthopedics, traumatology, maxillofacial surgery, and potentially pediatric surgery.

The biodrook team has completed an important milestone in the implementation of innovative technologies in medical manufacturing—specialized training on the setup and maintenance of a 3D printer designed for the production of non-resorbable polymer implants made of polyetheretherketone (PEEK).

PEEK is a high-tech biocompatible material actively used in reconstructive surgery of the face and skull, as well as in neurosurgery. Thanks to its unique properties, particularly its mechanical characteristics similar to those of bone tissue, it allows for the creation of customized solutions for complex clinical cases.

The PEEK processing procedure requires working at extremely high temperatures and strict adherence to technical parameters. All stages—from equipment setup to product manufacturing—are documented in production protocols to ensure maximum precision, reproducibility, and minimization of production risks.

The training was conducted by Dr. Lukas Umfer (Graz, Austria), a leading expert with many years of experience in the production of implants for cranial reconstruction. His work is based on the Point-of-Care approach—the fabrication of custom implants directly at the medical facility, which reduces the time between surgical planning and the procedure itself.

For biodrook, this training was a key step in developing internal expertise and

The biodrook team is proud to announce that our project has been recognized as one of Ukraine’s 25 most promising tech startups by Forbes. This achievement underscores the importance of our mission—to create fast, accessible, and innovative solutions for regenerative medicine.

biodrook has focused its efforts on producing 3D-printed bone implants that transform into the patient’s own bone tissue. Our solutions will be valuable to medical institutions treating patients with bone defects, particularly among military personnel. Thanks to mobile and stationary production platforms, implant manufacturing time has been reduced to 48 hours, allowing us to quickly meet needs even in the most remote parts of the country.

The company continues to grow rapidly, preparing to launch large-scale production in Ukraine and enter international markets. Our partners, such as Biopharma, The Mount Sinai Health System, DSM, and EVONIK, support us in introducing innovative technologies in Ukraine and integrating them into the medical sectors of the EU and the U.S.

Biodrook is grateful to Forbes for its high recognition and support of innovative solutions that help transform medicine today and in the future. We will continue working to make medical technologies accessible to everyone who needs them.

Stay tuned for our updates, because

We are pleased to announce that Biodrook has reached an important milestone in its development by securing a reliable investor and launching production operations at the Biopharma facility.

We sincerely thank Kostyantyn Yefimenko, the head of Biopharma, for his trust and support during this important phase. His belief in our mission has been key to the creation and development of Ukrainian biotechnology production.

We also express our deep gratitude to our board of directors. Their experience and dedication have helped us reach this important milestone.

This achievement would not have been possible without the dedication and support of everyone who believed in Biodrook from the very beginning. We sincerely thank our colleagues, partners, and experts who have been with us on this challenging journey and shared our dreams and ambitions.

On January 24, 2025, biodrook co-founder and CTO Mykhailo Pluzhnyk presented his report “Biopolymers in Real-World 3D Printing” at the IV International Symposium “Modern Technologies in Medical Materials Science in Orthobiology.” This event brought together leading experts in medical materials science, orthopedics, and regenerative medicine.

Mykhailo shared his experience using biopolymers in 3D printing, highlighted the latest industry trends, and discussed the innovations being developed and implemented as part of the biodrook project. It is gratifying that this presentation made a significant contribution to expanding knowledge about additive technologies in regenerative medicine.

Special attention should be paid to the scale of the event, which served as a platform for the exchange of ideas among leading scientists, doctors, and technologists. We are grateful to the organizers—the Bogomolets National Medical University and the relevant institutes—for the opportunity to be part of this incredible initiative. Special thanks to Volodymyr Serhiyovych Chorny.

We also express our gratitude to the other speakers who shared their knowledge and experience, as it is precisely through such collaboration that the conditions for breakthrough discoveries are created.

Stay tuned for updates to learn more about our participation in similar events and the achievements of the biodrook team!

Translated with DeepL.com (free version)

Standardized implants often fail to take the most important factor into account—the patient.

Customized shape modeling, biocompatible materials, and surgical precision are not the future, but a modern requirement for bone reconstruction. At biodrook, we are convinced that personalized solutions are what reduce postoperative pain, accelerate healing, and prevent repeat procedures.

Unlike traditional titanium or universal implants, we use two types of biopolymers—bioresorbable and non-bioresorbable—depending on the clinical task and the patient’s needs. Products are custom-made based on medical images, and production is fully localized in Ukraine.

Just as with the development of antibiotics, a true breakthrough in bone surgery occurs when technology adapts to living biology, rather than the other way around. Every patient should receive a solution that corresponds specifically to their anatomy, age, and bone tissue condition.

That is why we do not offer a “one-size-fits-all” solution. Our manufacturing platform enables scalable customization—implants tailored to a specific individual, yet produced quickly, precisely, and in compliance with all medical standards.

We are expanding our manufacturing operations in Ukraine and seeking partnerships with clinics and research teams.

The future is personalized. And it is already in the clinical trial stage Translated with DeepL.com (free version)

Category: Без рубрики